Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting an annualized return of 12.85%, outperforming a steady 10% growth benchmark. Key growth drivers include robust earnings beats, a promising drug pipeline, and international market expansion, though risks like pricing pressures, competition, and high valuation remain. Upcoming milestones such as the retatrutide filing and Foundayo launch in 2027 are expected to influence future performance.
As of Oct 20, 2026 22:41 WIB, Eli Lilly (LLY) shares trade at USD 1,299.12 on Pluang, showing a strong 1-day gain of 4.74%. The company holds a market cap of $1.11 trillion and an enterprise value of $1.15 trillion, with a dividend yield of 0.56%. Despite 80% of Pluang order activity being sell orders, the stock’s recent price strength highlights ongoing investor interest in the health sector giant.
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
Eli Lilly announced positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children aged 6 to 17 with moderately to severely active ulcerative colitis. In the SHINE-2 study, 81% of patients responded at 12 weeks, and 50% of responders achi...
Eli Lilly announced new clinical data presentations at the 2026 European Society for Medical Oncology (ESMO) Congress, featuring updates on several investigational and approved cancer therapies. Key highlights include Phase 1 data for sofetabart mipi...
Eli Lilly transformed from a traditional insulin maker into a pharmaceutical giant, driven by its obesity drug Tirzepatide, sold as Mounjaro and Zepbound. These drugs generated $14.9 billion in Q2 2026 alone, capturing 60% of U.S. obesity prescriptio...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
